Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00503581 · ClinicalTrials.gov registry record · Phase 2
Megestrol in Treating Patients With Endometrial Neoplasia or Endometrial Hyperplasia
A Phase 2 study, sponsored by Gynecologic Oncology Group.
- Terminated
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
NCT00503581 is a Phase 2 study that was terminated before completion, run by Gynecologic Oncology Group. The registered enrollment target is 9 participants.
The verdict
NCT00503581, a Phase 2 study, was terminated before completion, sponsored by Gynecologic Oncology Group.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
Study Summary
This randomized phase II trial is studying how well megestrol works in treating patients with endometrial neoplasia or endometrial hyperplasia. Estrogen can cause the growth of endometrial cancer cells. Hormone therapy using megestrol may fight endometrial cancer by blocking the use of estrogen by the abnormal cells.
Interventions
- OTHER Quality-of-Life Assessment
- PROCEDURE Biopsy
- OTHER Laboratory Biomarker Analysis
- DRUG Megestrol Acetate
- OTHER Pharmacological Study
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2007-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00503581
The ClinicalTrials.gov registry entry for NCT00503581 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gynecologic Oncology Group, which has 154 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Quality-of-Life Assessment is the first listed.
NCT00503581 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00503581 about?
NCT00503581 is a clinical study titled "Megestrol in Treating Patients With Endometrial Neoplasia or Endometrial Hyperplasia". This randomized phase II trial is studying how well megestrol works in treating patients with endometrial neoplasia or endometrial hyperplasia. Estrogen can cause the growth of endometrial cancer cells. Hormone therapy using megestrol may fight endometrial cancer by blocking the use of estrogen by t...
What is the current status of trial NCT00503581?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2007-07.
What interventions are being tested in trial NCT00503581?
The interventions under investigation include: Quality-of-Life Assessment (OTHER), Biopsy (PROCEDURE), Laboratory Biomarker Analysis (OTHER), Megestrol Acetate (DRUG), Pharmacological Study (OTHER).
Who is sponsoring clinical trial NCT00503581?
This trial is sponsored by Gynecologic Oncology Group, which has 154 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.